The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial
Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime E. C. Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Dráulio Barros de Araújo
Frontiers in Pharmacology November 19, 2019 DOI: 10.3389/fphar.2019.01325 via OpenAlex
Summary
AI-generated from the abstractA single dose of ayahuasca, compared with placebo, was associated with medium-to-large reductions in suicidality among 29 adults with treatment-resistant depression. Suicidality was assessed by a psychiatrist before the intervention and at one, two, and seven days afterward. The between-group effect sizes (ayahuasca versus placebo) were medium at each time point (Cohen's d = 0.58, 0.56, and 0.67), and the within-group effect sizes for those receiving ayahuasca were large (Cohen's d = 1.33, 1.42, and 1.19). The group-by-time interaction was not statistically significant, suggesting the findings should be interpreted cautiously. The authors conclude that ayahuasca may hold potential as an intervention for suicidality, while noting important limitations and the need for further research.
Study at a glance
| Characteristics | Randomized placebo-controlled trial Peer reviewed |
|---|---|
| Sample size | 29 |
| Population | Adults with treatment-resistant depression |
| Intervention | Ayahuasca |
| Dose | one dose |
| Duration | 7-day follow-up |
| Topics | Ayahuasca |
| Keywords | Placebo Depression economics Psychological intervention Randomized controlled trial |
| Citations | 79 |
| Registration | NCT02914769 |
| Key finding | Ayahuasca produced medium-to-large reductions in suicidality compared with placebo at one, two, and seven days after a single dose, although the group-by-time interaction was not statistically significant. |
Abstract
Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in which individuals with treatment-resistant depression were administered one dose of ayahuasca (n = 14) or placebo (n = 15). Suicidality was assessed by a trained psychiatrist at baseline, as well as 1 day, 2 days, and 7 days after the intervention. A fixed-effects linear mixed model, as well as between and within-groups Cohen's d effect sizes were used to examine changes in suicidality. Controlling for baseline suicidality, we found a significant effect for time (p p = .088). At all time points, we found medium between-group effect sizes (i.e., ayahuasca vs. placebo; day 1 Cohen's d = 0.58; day 2 d = 0.56; day 7 d = 0.67), as well as large within-group (ayahuasca; day 1 Cohen's d = 1.33; day 2 d = 1.42; day 7 d = 1.19) effect sizes, for decreases in suicidality. Conclusions: This research is the first to explore the impact of ayahuasca on suicidality. The findings suggest that ayahuasca may show potential as an intervention for suicidality. We highlight important limitations of the study, potential mechanisms, and future directions for research on ayahuasca as an intervention for suicidality. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02914769.